Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

Core Insights - Rani Therapeutics announced the presentation of preclinical data on the RaniPill® capsule at the Endocrine Society's Annual Meeting (ENDO 2025) [1][2] - The focus of the presentation is on the oral delivery of a bispecific GLP-1/GLP-2 receptor agonist (PG-102) via a robotic pill (RT-114), which achieved bioequivalence to subcutaneous injection in canines [1] Company Overview - Rani Therapeutics is a clinical-stage biotherapeutics company that specializes in the oral delivery of biologics and drugs [3] - The company has developed the RaniPill® capsule, a proprietary and patented platform technology aimed at replacing subcutaneous injections or intravenous infusions with oral dosing [3] - Rani has conducted several preclinical and clinical studies to assess the safety, tolerability, and bioavailability of the RaniPill® capsule technology [3]